Data InterpretationThe addition of ATYR0101 to the development pipeline builds on the promising clinical results of the company's lead tRNA synthetase-derived therapy, efzofitimod, for the treatment of interstitial lung disease (ILD), currently in pivotal Phase 3 studies.
Data UncertaintyThe company did not provide specifics regarding the dose used in the patients, leading to some uncertainty in data interpretation.
Short-Term Data ConcernMinimal clinically important difference for SSc-ILD is an improvement of 4-6 points at 12 months, contrasting with the shorter-term data presented.